Spotlight on Rheumatology

Credits: 0.75 CME / MOC
The Lupus Hub: Primary Care’s Pivotal Role in SLE
Louis Kuritzky, MD
The France Foundation

The Lupus Hub: Primary Care’s Pivotal Role in SLE

Start

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

Rheumatology Presentations

0.75 CME / CNE
Purdue University
The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

The Advances in Monoclonal Antibody Therapeutics to Improve Outcomes in Patients with Psoriatic Arthritis and Ankylosing Spondylitis

Start

Activity Details

Free CME/CNE
0.75 AMA PRA Category 1 Credit
0.75 CNE Contact Hour
Released: December 10, 2018
Expires: February 24, 2020
45 minutes to complete

Co-provided By

Target Audience

Rheumatologists, primary care physicians, internists, nurse practitioners, nurses, physician assistants, and other healthcare professionals involved in the management of patients with psoriatic arthritis and ankylosing spondylitis.

Learning Objectives

  1. Understand the immunopathology of PsA and AS, as well as early and accurate diagnosing, and disease monitoring
  2. Analyze clinical trial data of current and emerging therapeutic options for the management of PsA and AS
  3. Implement effective and safe treatment plans to improve outcomes in patients with PsA and AS

Activity Description

This CME/CNE activity is derived from content presented at the International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) Annual Meeting in Dallas, Texas. The expert faculty, Dr. Alvin F. Wells, will review the characteristics of both psoriatic arthritis (PsA) and ankylosing spondylitis (AS) to ensure accurate detection and early diagnosis. Recent guidelines for the treatment and management of PsA and AS patients will be analyzed, along with approved and emerging therapeutic options and their clinical relevance. Dr. Wells will relay best practices for switching therapies and managing the adverse events associated with approved therapies utilizing the interprofessional team. At the conclusion of this activity, clinicians will become better acquainted with optimal treatment strategies to improve their care of psoriatic arthritis and ankylosing spondylitis patients.

Statement of Educational Need

Health care team members need to understand the most recent clinical trial data regarding the treatment of management of patients with psoriatic arthritis and ankylosing spondylitis.

Agenda

  1. Psoriatic Arthritis and Ankylosing Spondylitis Update: Immunopathology, Accurate Diagnosing and Disease Monitoring
  2. Clinical Analysis of Current and Emerging Therapeutic Options for PsA and AS
  3. Implementing Safe and Effective Treatment Strategies to Improve Outcomes in Patients

Faculty

Alvin F. Wells, MD, PhD
Alvin F. Wells, MD, PhD
Visiting Foreign Professor, Karolinska Institute
Stockholm, Sweden
Adjunct Assistant Professor, Duke University Medical Center
Director, Rheumatology and Immunotherapy Center
Assistant Clinical Professor, Marquette University
Milwaukee, Wisconsin


Disclosures of Conflict of Interest

All faculty AND staff involved in the planning, review or presentation of continuing education activities sponsored/provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, reviewers, Purdue and AcademicCME staff have nothing to disclose.

Alvin F. Wells, MD, PhD

Consultant/Advisor: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB. Speaker’s Bureau: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Crescendo Bioscience, Inc.; Forest Laboratories; Genentech; GlaxoSmithKline; Janssen Scientific Affairs LLC; Lilly USA, LLC; Pfizer Inc.; Quest Diagnostics; Regeneron; Sanofi; Takeda Pharmaceutical Company Limited; UCB.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Purdue University College of Pharmacy and AcademicCME, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purdue University Continuing Nursing Education is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This program has been approved for 0.75 contact hour.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions.
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Healthcare providers who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME/CNE Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
  7. Healthcare providers should claim only the credit commensurate with the extent of their participation in the activity.
  8. 60 minutes of participation = 1 CNE contact hour

Statement of Commercial Support

This activity is supported by independent educational grants from Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME; Purdue University College of Pharmacy; Janssen Global Services LLC; Lilly USA, LLC; and Novartis Pharmaceuticals Corporation do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CNE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

0.75 CME
Postgraduate Institute for Medicine
Global Perspectives in RA: The Role of New Biologics for Optimal Management

Global Perspectives in RA: The Role of New Biologics for Optimal Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credits
Released: August 30, 2018
Expires: August 29, 2019
45 minutes to complete

Jointly Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Media

Internet

Target Audience

Clinicians involved in the care of patients with rheumatoid arthritis (RA).

Learning Objectives

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
  • Develop individualized RA treatment strategies that incorporate patient preferences, shared decision making, and patient education

 

Faculty

Paul Emery, MA, MD, FRCP, FMedSci (Chair)
Arthritis Research UK Professor of Rheumatology
Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds
Director, Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds, England (UK)


Jonathan Kay, MD
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, Massachusetts (USA)


Josef S. Smolen, MD
Professor of Medicine
Chairman, Division of Medicine and Department of Medicine 3
Medical University of Vienna
Vienna, Austria (Europe)


Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Paul Emery, MA, MD, FRCP, FMedSci, has affiliations with AbbVie, BMS, MSD, Pfizer, and Roche (Contracted Research/Grants); AbbVie, BMS, MSD, Novartis, Pfizer, Roche, and UCB (Consulting Fees); and AbbVie, BMS, MSD, Novartis, Roche, and UCB (Speakers' Bureau).
  • Jonathan Kay, MD, has affiliations with Eli Lilly and Company, Gilead, Pfizer, and UCB (Contracted Research/Grants); and Amgen, Boehringer Ingelhelm GmbH, Celgene, Celltrion Healthcare, Janssen, Merck Sharpe & Dohme, Myriad Genetics, Pfizer, Roche, Samsung Bioepis, and Sandoz (Consulting Fees). 
  • Josef S. Smolen, MD, has affiliations with AbbVie, Astra-Zeneca, Eli Lilly and Company, Janssen, MSD, Pfizer, and Roche (Contracted Research/Grants); and AbbVie, Amgen, Astra-Zeneca, Astro, BMS, Celgene, Celltrion, Chugai, Gilead, Glaxo, Eli Lilly and Company, ILTOO, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi, and UCB (Consulting Fees).

Planners and Managers
The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.


PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Receive Credit

By reviewing the course content and successfully completing the post-test and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. If you would like to contact Postgraduate Institute for Medicine, please email information@pimed.com.

YOUR FEEDBACK IS IMPORTANT!

Complete the Evaluation form for this activity and be entered into a drawing for a $100* Amazon Gift card.
*The expense for this gift card is solely funded by RMEI Medical Education, LLC. No supporter funding was used for the expense of this gift card.

Rules and Regulations 
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a monthly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your email address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

The activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.

1.50 CME
Postgraduate Institute for Medicine
Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Early and Aggressive Approaches to RA Management to Minimize Disease Progression and Improve Quality of Life

Start

Activity Details

Free CME
1.5 AMA PRA Category 1 Credits
Released: May 1, 2018
Expires: June 17, 2019
1.5 hours to complete

Faculty

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Iain B. McInnes, PhD, FRCP, FRSE, FMedSci
Muirhead Chair of Medicine
Director of the Institute of Infection, Immunity, and Inflammation
University of Glasgow
Glasgow, Scotland


Marc D. Cohen, MD
Marc D. Cohen, MD
Emeritus Professor of Medicine, Mayo Clinic
Rochester, Minnesota
Adjunct Professor of Medicine
Division of Rheumatology, National Jewish Health
Denver, Colorado


Jeffrey R. Curtis, MD
Jeffrey R. Curtis, MD
Professor of Medicine
The William J. Koopman Endowed Professor
in Rheumatology and Immunology
Director, Arthritis Clinical Intervention Program
University of Alabama at Birmingham
Birmingham, Alabama


Jointly provided by

Commercial Support Statement

This activity is supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Method of Participation

Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via email or you may print it out at that time.

Inquiries may be directed to Global Academy for Medical Education at info@globalacademycme.com or (973) 290-8225 or the Postgraduate Institute for Medicine at (720) 895-5357.

Joint Accreditation Statement

Accreditation Council for Pharmacy Education In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Global Academy for Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

This enduring activity is intended for rheumatologists, internal medicine physicians with a secondary specialty in rheumatology, physician assistants, and other clinicians who treat patients with rheumatic diseases.

Educational Needs

Clinical studies on patients with rheumatoid arthritis have consistently found that patients are more likely to respond and more likely to reach remission if they are treated with disease-modifying antirheumatic drugs (DMARDs) within 3 to 6 months of symptom onset. But studies of patients in clinical practice find that diagnosis is often delayed, and typically treatment begins a year or more after symptom onset. Clinicians need information on strategies to enable earlier treatment. Guidelines also recommend a treat-to-target approach with a goal of sustained remission. This approach requires ongoing monitoring and treatment changes to meet patient needs. New medications have been approved recently, adding to the rheumatologist’s armamentarium for treating rheumatoid arthritis.

Learning Objectives

At the conclusion of this program, participants should be better able to:

  • Design appropriate strategies to increase the timeliness of rheumatoid arthritis diagnosis and subsequent linkage to evidence-based care
  • Design appropriate strategies to relieve articular and systemic symptoms of rheumatoid arthritis
  • Design strategies for using the most appropriate therapies based on the safety and efficacy data of the emerging classes of therapies for rheumatoid arthritis, including anti-interleukin (IL)-6/IL-6R agents, tumor necrosis factor (TNF) inhibitors, and other biologic disease-modifying antirheumatic drugs (DMARDs)
  • Design treatment strategies for rheumatoid arthritis that take into consideration recommendations from current guidelines and emerging data from clinical trials
  • Describe the data presented at national and global scientific conferences that may help clinicians achieve the treatment goals for rheumatoid arthritis

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

Marc D. Cohen, MD, has nothing to disclose.

Jeffrey R. Curtis, MD, Consultant: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Pfizer, and UCB. Grant/Research Support: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo Bioscience, Ortho-McNeil-Janssen Pharmaceuticals, Roche/Genentech, Pfizer, and UCB.

Iain B. McInnes, PhD, FRCP, FRSE, FMedSci, Consultant: AbbVie, Galapagos, Lilly, and Pfizer. Grant/Research Support: Bristol-Myers Squibb, Janssen, Pfizer, and UCB.

The planning staff and content managers hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Global Academy for Medical Education Staff: Mike LoPresti; Shirley V. Jones, MBA; and Margaret McLauglin, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Postgraduate Institute for Medicine: planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME / MOC
The France Foundation
The Lupus Hub: Primary Care’s Pivotal Role in SLE

The Lupus Hub: Primary Care’s Pivotal Role in SLE

Start

Activity Details

Free CME/MOC
.75 AMA PRA Category 1 Credit(s)™/
MOC point(s)
Released: December 18, 2018
Expires: December 17, 2019
45 minutes to complete

Accredited By

Target Audience

This educational initiative is intended for primary care clinicians who care for adult patients with SLE.

Learning Objectives

  1. Describe key evidence-based strategies for diagnosing SLE.
  2. Utilize effective strategies to assess and co-manage patients with SLE over time.
  3. Summarize key aspects of established treatments for SLE.
  4. Monitor the patient for treatment side effects.
  5. Formulate a plan for communication with patients about SLE and its treatment, including methods for facilitating treatment adherence.

Activity Description

Autoimmune diseases are difficult to diagnose. Lupus, in particular, is complicated as its symptoms are common to a variety of other conditions. Diagnosing lupus with any degree of accuracy can be challenging and costly. This activity will orient the primary care provider on how to accurately diagnose systemic lupus erythematosus (SLE), further providing guidance on management strategies and doctor-patient communication, specifically with the goal of increasing treatment adherence in patients.

Agenda

  1. Recognizing SLE: Primary Care Approach to Diagnostic Criteria
    How to recognize the condition based on ACR criteria.
  2. Assessing a Moving Target: SLE Evaluation Over Time
    Signs of disease progression; when to recommend further evaluation.
  3. Answering the “Whats” and “Whens” of Management
    Understanding treatment options, facilitating specialist consultation, and monitoring for treatment side effects.
  4. Keeping the Lines Open: Practical Strategies for Communication and Facilitating Adherence
    What are effective communication techniques (eg, AHRQ’s “Teach Back” method, particular phrasing for adherence-related questions, encouraging patient-generated questions) that can address sensitive or challenging issues? Applying practical patient-centered approaches as a means to facilitate treatment adherence.

Faculty

Louis Kuritzky, MD
Louis Kuritzky, MD
Content Creator and Activity Presenter
Clinical Assistant Professor Emeritus
Department of Community Health and Family Medicine
University of Florida, Gainesville
Gainesville, Florida

Disclosure:
Louis Kurtizky, MD, has no relevant financial relationships to disclose.


Daniel J. Wallace, MD, FACP, MACR
Daniel J. Wallace, MD, FACP, MACR
Content Creator
Associate Director, Rheumatology Fellowship Program
Board of Governors, Cedars-Sinai Medical Center
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center at UCLA
In affiliation with Attune Health
Los Angeles, California

Disclosure:
Daniel J. Wallace, MD, FACP, MACR, has served as an advisor for Amgen, EMD Serono, Celgene, Merck, Lilly.


MOC Reviewer

Richard Sadovsky, MD, MS
Associate Professor of Family Medicine
SUNY-Downstate Medical center

Disclosure:
Richard Sadovsky, MD, has no relevant financial relationships to disclose.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. The France Foundation resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, The France Foundation seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. The France Foundation is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The France Foundation designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 MOC point(s) in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC point(s) equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting MOC credit, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.

Statement of Commercial Support

This activity is supported by an educational grant from GlaxoSmithKline.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation requires CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. The France Foundation does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions about the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Hardware/Software Requirements

Pro-CME recommends using the latest versions of these supported browsers: Google Chrome, Microsoft Internet Explorer, Mozilla Firefox, Safari. Depending on your browser of choice, additional software, such as Adobe Reader® and Adobe® Flash® Player may be required.